Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04681079 · ClinicalTrials.gov registry record
Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19
A clinical trial, sponsored by Theravance Biopharma.
- Completed
- Registry status
- 14
- Enrollment target
NCT04681079 is a clinical trial that has completed, run by Theravance Biopharma. The registered enrollment target is 14 participants.
The verdict
NCT04681079 has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
A randomized, 2-period crossover, single-center, open-label study for viral sample collection. After initiation of inhaled therapy with nebulizer or MDI, cascade impactors and surface samplers will be used to assess viral loads in rooms of subjects with COVID-19.
Interventions
- DRUG albuterol sulfate (MDI)
- DRUG albuterol sulfate (nebulizer)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-05-04 |
| Est. Completion | 2022-01-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04681079
The ClinicalTrials.gov registry entry for NCT04681079 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which albuterol sulfate (MDI) is the first listed.
NCT04681079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04681079 about?
NCT04681079 is a clinical study titled "Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19". A randomized, 2-period crossover, single-center, open-label study for viral sample collection. After initiation of inhaled therapy with nebulizer or MDI, cascade impactors and surface samplers will be used to assess viral loads in rooms of subjects with COVID-19.
What is the current status of trial NCT04681079?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2021-05-04. Estimated completion is 2022-01-18.
What interventions are being tested in trial NCT04681079?
The interventions under investigation include: albuterol sulfate (MDI) (DRUG), albuterol sulfate (nebulizer) (DRUG).
Who is sponsoring clinical trial NCT04681079?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.